The effect of dose titration of LY2189265 in overweight and obese patients with type 2 diabetes mellitus

Trial Profile

The effect of dose titration of LY2189265 in overweight and obese patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2014

At a glance

  • Drugs Dulaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms EGO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Sep 2010 Results from an exploratory analysis investigating the differences in outcomes between Hispanics and Caucasians were reported at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 16 Dec 2009 Actual patient number from 262 to 266 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top